Znaczenie badania LIFE dla codziennej praktyki Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2009
Słowa kluczowe:
losartan, atenolol, nadciśnienie tętnicze, przerost lewej komory serca
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono główne wyniki badania The Losartan Intervention for Endpoint Study, w którym po raz pierwszy porównano skuteczność losartanu i atenololu w terapii chorych z nadciśnieniem i współistniejącym przerostem lewej komory serca, wykazano wyższość sartanu w redukcji ryzyka udarów, rozwoju nowych przypadków cukrzycy i migotania przedsionków oraz regresji przerostu. Rezultaty LIFE Study stanowiły podstawę do szerokiego stosowania sartanów w terapii nadciśnienia tętniczego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grodzicki , T. (2009). Znaczenie badania LIFE dla codziennej praktyki . Medycyna Faktów , 2(4(5), 46-50. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2631
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
2. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J.M., Snapinn S. (for the LIFE study group): Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 2002; 20: 1879-86.
3. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe- Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., Wedel H., LIFE (Losartan Intervention for Endpoint Reduction) Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
4. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S., LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
5. Lindholm L.H., Dahlof B., Edelman J.M., Ibsen H., Borch-Johnsen K., Olsen M.H., Snapinn S., Wachtell K., LIFE study group: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619-20.
6. Fuchs F.D.: Losartan for cardiovascular disease in patient’s with and without diabetes in the LIFE study. Lancet 2002; 359: 2203.
7. Devereux R.B., Dahlof B., Kjeldsen S.E., Julius S., Aurup P., Beevers G., Edelman J.M., de Faire U., Fyhrquist F., Helle Berg S., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., Wedel H., LIFE Study Group: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. 2003; 139: 169-77.
8. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Okin P.M., Omvik P., Oparil S., Wedel H., Snapinn S.M., Aurup P.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003; 139: 901-6.
9. Wachtell K., Palmieri V., Olsen M.H., Bella J.N., Aalto T., Dahlof B., Gerdts E., Wright J.T. Jr, Papademetriou V., Mogensen C.E., Borch-Johnsen K., Ibsen H., Devereux R.B.: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am. Heart J. 2002; 143: 319-26.
10. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M., Dahlof B.: Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-90.
11. Devereux R.B., Palmieri V., Liu J.E., Wachtell K., Bella J.N., Boman K., Gerdts E., Nieminen M.S., Papademetriou V., Dahlof B.: Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J. Hypertens. 2002; 20: 1445-50.
12. Wachtell K., Dahlof B., Rokkedal J., Papademetriou V., Nieminen M.S., Smith G., Gerdts E., Boman K., Bella J.N., Devereux R.B.: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am. Heart J. 2002; 144: 1057-64.
13. Palmieri V., Wachtell K., Gerdts E., Bella J.N., Papademetriou V., Tuxen C., Nieminen M.S., Dahlof B., de Simone G., Devereux R.B.: Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am. Heart J. 2001; 141: 784-91.
14. Wachtell K., Bella J.N., Rokkedal J., Palmieri V., Papademetriou V., Dahlof B., Aalto T., Gerdts E., Devereux R.B.: Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105: 1071-6.
15. Wachtell K., Palmieri V., Olsen M.H., Gerdts E., Papademetriou V., Nieminen M.S., Smith G., Dahlof B., Aurigemma G.P., Devereux R.B.: Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002; 106: 227-32.
16. Palmieri V., Okin P.M., Bella J.N., Gerdts E., Wachtell K., Gardin J., Papademetriou V., Nieminen M.S., Dahlof B., Devereux R.B; Losartan Intervention For Endpoint reduction in hypertension: Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Hypertension 2003; 41: 75-82.
17. Oikarinen L., Nieminen M.S., Viitasalo M., Toivonen L., Wachtell K., Papademetriou V., Jern S., Dahlof B., Devereux R.B., Okin P.M.: Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J. Hypertens. 2001; 19: 1883-91.
18. Oikarinen L., Nieminen M.S., Toivonen L., Viitasalo M., Wachtell K., Papademetriou V., Jern S., Dahlof B., Devereux R.B., Okin P.M.; LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients. the Losartan Intervention For Endpoint Reduction (LIFE) study. Am. Heart J. 2003; 145: 919-25.
19. Gerdts E., Bjornstad H., Toft S., Devereux R.B., Omvik P.: Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J. Hypertens. 2002; 20: 1223-9.
2. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J.M., Snapinn S. (for the LIFE study group): Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 2002; 20: 1879-86.
3. Kjeldsen S.E., Dahlof B., Devereux R.B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe- Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., Wedel H., LIFE (Losartan Intervention for Endpoint Reduction) Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
4. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S., LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
5. Lindholm L.H., Dahlof B., Edelman J.M., Ibsen H., Borch-Johnsen K., Olsen M.H., Snapinn S., Wachtell K., LIFE study group: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619-20.
6. Fuchs F.D.: Losartan for cardiovascular disease in patient’s with and without diabetes in the LIFE study. Lancet 2002; 359: 2203.
7. Devereux R.B., Dahlof B., Kjeldsen S.E., Julius S., Aurup P., Beevers G., Edelman J.M., de Faire U., Fyhrquist F., Helle Berg S., Ibsen H., Kristianson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Snapinn S., Wedel H., LIFE Study Group: Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann. Intern. Med. 2003; 139: 169-77.
8. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Okin P.M., Omvik P., Oparil S., Wedel H., Snapinn S.M., Aurup P.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 2003; 139: 901-6.
9. Wachtell K., Palmieri V., Olsen M.H., Bella J.N., Aalto T., Dahlof B., Gerdts E., Wright J.T. Jr, Papademetriou V., Mogensen C.E., Borch-Johnsen K., Ibsen H., Devereux R.B.: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am. Heart J. 2002; 143: 319-26.
10. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M., Dahlof B.: Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-90.
11. Devereux R.B., Palmieri V., Liu J.E., Wachtell K., Bella J.N., Boman K., Gerdts E., Nieminen M.S., Papademetriou V., Dahlof B.: Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J. Hypertens. 2002; 20: 1445-50.
12. Wachtell K., Dahlof B., Rokkedal J., Papademetriou V., Nieminen M.S., Smith G., Gerdts E., Boman K., Bella J.N., Devereux R.B.: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am. Heart J. 2002; 144: 1057-64.
13. Palmieri V., Wachtell K., Gerdts E., Bella J.N., Papademetriou V., Tuxen C., Nieminen M.S., Dahlof B., de Simone G., Devereux R.B.: Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am. Heart J. 2001; 141: 784-91.
14. Wachtell K., Bella J.N., Rokkedal J., Palmieri V., Papademetriou V., Dahlof B., Aalto T., Gerdts E., Devereux R.B.: Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105: 1071-6.
15. Wachtell K., Palmieri V., Olsen M.H., Gerdts E., Papademetriou V., Nieminen M.S., Smith G., Dahlof B., Aurigemma G.P., Devereux R.B.: Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002; 106: 227-32.
16. Palmieri V., Okin P.M., Bella J.N., Gerdts E., Wachtell K., Gardin J., Papademetriou V., Nieminen M.S., Dahlof B., Devereux R.B; Losartan Intervention For Endpoint reduction in hypertension: Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Hypertension 2003; 41: 75-82.
17. Oikarinen L., Nieminen M.S., Viitasalo M., Toivonen L., Wachtell K., Papademetriou V., Jern S., Dahlof B., Devereux R.B., Okin P.M.: Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J. Hypertens. 2001; 19: 1883-91.
18. Oikarinen L., Nieminen M.S., Toivonen L., Viitasalo M., Wachtell K., Papademetriou V., Jern S., Dahlof B., Devereux R.B., Okin P.M.; LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients. the Losartan Intervention For Endpoint Reduction (LIFE) study. Am. Heart J. 2003; 145: 919-25.
19. Gerdts E., Bjornstad H., Toft S., Devereux R.B., Omvik P.: Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J. Hypertens. 2002; 20: 1223-9.